Case Report

Significant Absorption of Oral Vancomycin in a Patient with Clostridium difficile Colitis and Normal Renal Function

Authors: Sangita Aradhyula, MD, Farrin A. Manian, MD, Saad A.S. Hafidh, MD, Saqib S. Bhutto, MD, Martin A. Alpert, MD

Abstract

Orally-administered vancomycin is poorly absorbed in most patients, usually producing minimal or subtherapeutic serum concentrations. Bowel inflammation may enhance absorption of oral vancomycin, particularly in those with renal failure. A 77-year-old female with Clostridium difficile (C difficile) colitis and normal renal function was treated with high doses of oral vancomycin and achieved serum concentrations in the therapeutic range. To our knowledge, this is the first report of a patient with C difficile colitis and normal renal function to develop therapeutic serum concentrations following oral administration of vancomycin.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Kyne L, Farrell RJ, Kelly CP. Clostridium difficile. Gastroenterol Clin North Am 2001;30:753–777.
 
2. Hirschhorn LR, Trnka Y, Onderdonk A, et al. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994;169:127–133.
 
3. Samore MH. Epidemiology of nosocomial Clostridium difficile diarrhoea. J Hosp Infect 1999;43:S183–S190.
 
4. Lai KK, Melvin ZS, Menard MJ, et al. Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control. Infect Control Hosp Epidemiol 1997;18:628–632.
 
5. Fekety R, Kim KH, Brown D, et al. Epidemiology of antibiotic associated colitis: isolation of Clostridium difficile from the hospital environment. Am J Med 1981;70:906–908.
 
6. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002;35:690–696.
 
7. Pelaez T, Alcala L, Alonso R, et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002;46:1647–1650.
 
8. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586–1590.
 
9. Thomson G, Clark AH, Hare K. Pseudomembranous colitis after treatment with metronidazole. Br Med J 1981;282:864–865.
 
10. Wilhelm MP, Estes L. Symposium on antimicrobial agents, XII: vancomycin. Mayo Clinic Proc1999;74:928–935.
 
11. Spitzer PG, Eliopoulos GM. Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis. Ann Intern Med 1984;100:533–534.
 
12. Kucers A, Bennett NM. Vancomycin. In: Kucers A, Bennett NM, eds. The Use of Antibiotics: A Comprehensive Review with Clinical Emphasis. 4th ed. Philadelphia, JB Lippinott Co, 1987, pp 1045–1068.
 
13. McHenry MC, Govan TL,. Vancomycin. Pediatr Clin North Am 1983;30:31–47.
 
14. Moellering RC Jr. Monitoring serum vancomycin levels: climbing the mountain because it is there?Clin Infect Dis 1994;18:544–546.
 
15. Cook FV, Farrar WE Jr. Vancomycin revisited. Ann Intern Med 1978;88:813.–818.
 
16. Bryan CS, White WL. Safety of oral vancomycin in functionally anephric patients. Antimicrob Agents Chemother 1978;14:634–635.
 
17. Geraci JE, Heilman FR, Nichols DR, et al. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Mayo Clin Proc 1956;31:564–582.
 
18. Tedesco F, Markham R, Gurwith M, et al. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 1978;2:226–228.
 
19. Dudley MN, Quintiliani R, Nightingale CH, et al. Absorption of vancomycin. Ann Intern Med1984;101:144.
 
20. Mackett RL, Guay DR. Vancomycin-induced neutropenia. Can Med Assoc J 1985;132:39–40.
 
21. Mandel DL, Garrison MW, Palpant SD. Agranulocytosis induced by vancomycin or ticarcillin/clavulinate. Ann Pharmacother 1997;11:1321–1324.
 
22. Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic-associated clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989;86:15–19.